Next Article in Journal
Potential Role of Microfibrillar-Associated Protein 4, Fibrotic Indices and Oxidative Stress in Hepatocellular Carcinoma
Previous Article in Journal
Structure-Antibacterial Activity Relationships of N-Substituted-(d-/l-Alaninyl) 1H-1,2,3-Triazolylmethyl Oxazolidinones
Article Menu

Export Article

Open AccessReview
Sci. Pharm. 2018, 86(4), 43; https://doi.org/10.3390/scipharm86040043

Pharmacokinetic Enhancers (Boosters)—Escort for Drugs against Degrading Enzymes and Beyond

Department of Pharmacy-Center for Drug Research, Ludwig-Maximilians University, Butenandtstr. 5-13, 81377 Munich, Germany
*
Author to whom correspondence should be addressed.
Received: 22 August 2018 / Revised: 19 September 2018 / Accepted: 20 September 2018 / Published: 27 September 2018
  |  
PDF [8722 KB, uploaded 29 September 2018]
  |  

Abstract

Pharmacokinetic enhancers (boosters) are compounds used in combination with a primary therapeutic agent (drug) and are not used for their direct effects on the disease but because they enhance or restore the activity of the primary agent. Hence, in certain cases, they represent an indispensable escort for enzyme-labile drugs. Pharmacokinetic enhancers can exert their activity on different ways. In the most common case, they inhibit enzymes such as human cytochrome P450 enzymes in the liver or other organs and, thereby, block or reduce undesired metabolism and inactivation of the primary drug. In this review, an overview will be given on the therapeutically most important classes of pharmacokinetic enhancers like β-lactamase inhibitors, inhibitors of CYP (cytochrome P450) enzymes in HIV therapy and hepatitis C, boosters for fluoropyrimidine-type anticancer agents, compounds utilized for enabling therapy of Parkinson’s disease with levodopa, and others. Inhibitors of efflux pumps in both pathogenic bacteria and tumor cells will be addresses shortly. View Full-Text
Keywords: pharmacokinetic enhancer; booster; enzyme; inhibitor; β-lactamase; DOPA decarboxylase; antibiotic; resistance; efflux pump; protease; antimetabolite pharmacokinetic enhancer; booster; enzyme; inhibitor; β-lactamase; DOPA decarboxylase; antibiotic; resistance; efflux pump; protease; antimetabolite
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Krauß, J.; Bracher, F. Pharmacokinetic Enhancers (Boosters)—Escort for Drugs against Degrading Enzymes and Beyond. Sci. Pharm. 2018, 86, 43.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top